ReviewAnnals of hematology2025
Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review.
Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Liposomal mitoxantrone, venetoclax and azacitidine in relapsed/refractory acute myeloid leukaemia and early induction failure: a single-centre real-world study.Frontiers in oncology · 2026Article
- Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is the most common type of acute leukemia, of which relapsed/refractory AML (R/R AML) is the major cause of death in these patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains to be the mainstay curative treatment for patients with R/R AML. However, the prognosis of R/R AML is still unsatisfactory. Systematic analysis of the clinical-biological management and characteristics throughout the HSCT process in R/R AML patients may break through the current predicament of poor prognosis. This review provides a holistic analysis of the complete clinical management process for R/R AML, from disease mechanisms to post-transplantation therapies. Novel conditioning and post-transplantation regimens incorporating target/immune-based therapies have improved outcomes of HSCT in R/R AML patients. The widespread adoption of haploidentical transplantation has ended the era of donor scarcity, while donor switching remain a critical clinical outcome for patients with second-transplantation. This study provides guidance for clinical decision-making, though further optimization of prognostic models and integration of novel biomarkers are needed to advance personalized treatment strategies for R/R AML patients in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.